T

Tyler Research Institute | Tyler, TX

Research site
(Unclaimed)
Location
1720 South Beckham, Tyler, Texas, United States of America
Site insights

Top conditions

Ulcer (27 trials)

Ulcerative Colitis (27 trials)

Colitis (27 trials)

Crohn Disease (25 trials)

Eosinophilic Esophagitis (2 trials)

Top treatments

Risankizumab
Guselkumab
Upadacitinib
ABT-494
Etrolizumab
Etrasimod
Mirikizumab
Vedolizumab
Adalimumab
AMT-101

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

27 of 53
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-2)

The reason for this study is to determine the long-term efficacy and safety of the study drug mirikizumab in participants with Crohn's disease.

Enrolling
Crohn's Disease
Drug: Mirikizumab

A multicenter study to evaluate the efficacy and safety of maintenance and long-term treatment administration of upadacitinib, an orally administered...

Active, not recruiting
Crohn's Disease
Drug: Upadacitinib
Drug: Placebo for Upadacitinib

This is a Phase 2/3 study that comprises 5 substudies designed to evaluate the efficacy, safety, and tolerability of oral etrasimod as therapy in adu...

Enrolling
Crohn's Disease
Drug: Etrasimod
Drug: Placebo

The purpose of this study is to evaluate the efficacy and safety of JNJ-78934804 as compared to guselkumab and golimumab in participants with moderat...

Enrolling
Colitis, Ulcerative
Drug: Placebo
Biological: Golimumab

The purpose of this study to evaluate the clinical efficacy of guselkumab in fistulizing, perianal Crohn's disease and to assess the overall safety o...

Enrolling
Perianal Crohns Disease
Fistulizing Crohns Disease
Drug: Placebo
Drug: Guselkumab

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active ulcerative colitis...

Active, not recruiting
Ulcerative Colitis
Drug: Guselkumab
Drug: Placebo

The purpose of this study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in...

Active, not recruiting
Colitis, Ulcerative
Other: Placebo
Drug: Guselkumab Dose 1

The purpose of this study is to evaluate the safety and effectiveness of JNJ-77242113 compared with placebo in participants with moderately to severe...

Enrolling
Colitis, Ulcerative
Drug: JNJ-77242113
Drug: Placebo

The main aim of the study is to check for long-term side effects of Vedolizumab Subcutaneous (also known as Vedolizumab SC) in people with ulcerative...

Active, not recruiting
Colitis, Ulcerative
Crohn's Disease
Drug: Vedolizumab SC

A study to investigate bowel urgency in adults with moderately to severely active ulcerative colitis (UC) treated with mirikizumab. The study will ha...

Enrolling
Ulcerative Colitis Chronic
Ulcerative Colitis
Drug: Mirikizumab

The purpose of this study is to evaluate the clinical efficacy (GALAXI 1), clinical and endoscopic efficacy (GALAXI 2 and GALAXI 3) and safety of gus...

Active, not recruiting
Crohn's Disease
Drug: Guselkumab Dose 3
Drug: Ustekinumab

The study consists of 4 sub-studies, as follows:Sub-study 1 (Randomized, double-blind, placebo controlled study) to evaluate the efficacy and safety...

Active, not recruiting
Crohn's Disease
Drug: Risankizumab SC
Drug: Risankizumab On-Body Injector (OBI)

Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate t...

Enrolling
Crohn's Disease
Drug: TAK-279
Drug: Placebo
Locations recently updated

Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the...

Enrolling
Crohn's Disease
Drug: Placebo for risankizumab
Drug: Risankizumab SC

The purpose of this study is to evaluate safety and efficacy of risankizumab in participants with ulcerative colitis (UC) in participants who respond...

Active, not recruiting
Ulcerative Colitis (UC)
Drug: risankizumab
Drug: placebo for risankizumab

Study CC-93538-EE-001 is a Phase 3, multicenter, multinational, randomized, double-blind, placebo-controlled induction and maintenance study to evalu...

Active, not recruiting
Eosinophilic Esophagitis
Drug: CC-93538
Other: Placebo

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of vixarelimab compared with placebo in participants with moderat...

Enrolling
Ulcerative Colitis
Drug: Placebo
Drug: Vixarelimab

This study is designed to evaluate the long-term safety and efficacy of Upadacitinib in participants with ulcerative colitis (UC) who have not respon...

Active, not recruiting
Ulcerative Colitis (UC)
Drug: Placebo
Drug: Upadacitinib (ABT-494)

This is a multicenter, randomized study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as mainten...

Enrolling
Ulcerative Colitis
Drug: Placebo
Drug: ABX464

This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinica...

Enrolling
Ulcerative Colitis
Drug: Placebo
Drug: ABX464

Trial sponsors

AbbVie logo

AbbVie (13 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems